COPENHAGEN (Reuters) - Denmark's Novo Nordisk lifted third-quarter core profit by 40 percent and above expectations on the back of strong sales of diabetes drug Victoza and modern insulins. The world's biggest insulin producer raised its 2012 sales growth forecast in local currencies to 10 to 12 percent from 9 to 12 percent and said it expected operating profit growth of 16 to 18 percent versus 15 percent previously. "Continued strong sales of our modern insulins and Victoza have led to a robust financial performance in the first nine months of 2012," Chief Executive Lars Sorensen said. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment